Microparticle-based transfection and activation of dendritic cells
CA 2392071 C · Owner: Denis-Mize, Kimberly Sue · Inventors: Denis-Mize, Kimberly Sue; Donnelly, John James; Ott, Gary Steven
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises a polynucleotide and microparticles with the , microparticles being comprised of biodegradable polymer and cationic detergent. The dendritic cells and transfection agent are incubated for a time sufficient to transfect the dendritic cells with the polynucleotide.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 17, 2000 and granted January 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 17, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 17, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.